Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Gross Margin (2017 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Gross Margin for 8 consecutive years, with 90.59% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin rose 233.0% year-over-year to 90.59%, compared with a TTM value of 88.26% through Dec 2025, down 33.0%, and an annual FY2025 reading of 88.26%, down 33.0% over the prior year.
  • Gross Margin was 90.59% for Q4 2025 at Agios Pharmaceuticals, up from 86.96% in the prior quarter.
  • Across five years, Gross Margin topped out at 92.34% in Q1 2024 and bottomed at 59.25% in Q1 2022.
  • Average Gross Margin over 4 years is 86.87%, with a median of 89.19% recorded in 2023.
  • Peak annual rise in Gross Margin hit 3087bps in 2023, while the deepest fall reached -871bps in 2023.
  • Year by year, Gross Margin stood at 90.42% in 2022, then rose by 1bps to 91.75% in 2023, then decreased by -4bps to 88.26% in 2024, then rose by 3bps to 90.59% in 2025.
  • Business Quant data shows Gross Margin for AGIO at 90.59% in Q4 2025, 86.96% in Q3 2025, and 86.33% in Q2 2025.